Cancer News

Twice-daily radiation therapy reduces mortality from head and neck cancer (02/14/2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with head and neck cancer worldwide each year. It can be difficult to treat because the area of the body …

Continue reading "Twice-daily radiation therapy reduces mortality from head and neck cancer"

Opdivo Approved for Advanced Head and Neck Cancer (11/28/2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the head and neck cancer (SCCHN) that has spread to distant sites in the body and has progressed or … Continue reading "Opdivo Approved for Advanced Head and Neck Cancer"

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (10/05/2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one cycle of chemotherapy. The ability to identify a patients response to chemotherapy early is … Continue reading "PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment"

Keytruda® Approved for Advanced Head and Neck Cancer (09/07/2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck squamous cell cancer … Continue reading "Keytruda® Approved for Advanced Head and Neck Cancer"

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer (06/09/2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published in the International Journal of Radiation Oncology, Biology, Physics. Head and neck cancer refers to several different … Continue reading "Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer"

Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer (06/08/2016)

Treatment with the immune-stimulating agent, Keytruda® (pembrolizumab), provides impressive long-term outcomes for some patients with metastatic or recurrent head and neck cancer. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Globally, head and neck cancer comprises the seventh most common type of cancer with an … Continue reading "Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer"

Follow-Up Scans Reduce Need for Some Invasive Surgeries in Head and Neck Cancer (06/06/2016)

Utilizing PET-CT scans following treatment for patients with head and neck cancer that has spread to their lymph nodes significantly reduces the need for invasive follow-up surgery. These results were recently published in the New England Journal of Medicine. Patients diagnosed with head and neck cancer (HNC) that has spread to nearby lymph nodes are … Continue reading "Follow-Up Scans Reduce Need for Some Invasive Surgeries in Head and Neck Cancer"

More Evidence that PD-1 Inhibitors Improve Survival in Head and Neck Cancer (05/25/2016)

Results from a recent large trial indicate that treatment with the immunotherapy agent Opdivo® (nivolumab) nearly doubles the survival rate at one year in patients with advanced head and neck squamous cell carcinoma. These results prompted the United States Food and Drug Administration to grant Opdivo “breakthrough therapy designation” for the treatment of patients with … Continue reading "More Evidence that PD-1 Inhibitors Improve Survival in Head and Neck Cancer"